BDB-001

DB16480

biotech investigational

Deskripsi

BDB-001, was under investigation in multiple clinical trials to evaluate its safety, tolerability, and efficacy across various conditions. In NCT05075304 and NCT04449588, BDB-001 was studied in mild to severe COVID-19 patients. It was also explored for solid tumors in NCT03486301, NCT04196530, and NCT04819373, either as monotherapy or combined with Pembrolizumab or Atezolizumab, and in NCT03915678 with Atezolizumab and immunogenic radiotherapy. Additionally, NCT05197842 investigated its use in ANCA-associated vasculitis, and NCT05103423 and NCT05093855 focused on moderate to severe Hidradenitis Suppurativa.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

0 Data
Tidak ada data.

Referensi & Sumber

Artikel (PubMed)
  • PMID: 36697937
    Chen G, Li N, Dai X, Tu S, Shen Z, Wu K, Jin T, Wu J, Peng C, Sheng G, Zhu M, Tang L, Li L: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Anti-C5a Antibody BDB-001 for Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Trial in Healthy Chinese Adults. Infect Dis Ther. 2023 Feb;12(2):663-675. doi: 10.1007/s40121-023-00759-4. Epub 2023 Jan 25.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul